Showing results (211-220 of 255) with videos related to

Sort By:
Pageof 26
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
JACC. Heart Failure|February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline CharacteristicsPablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
Nature Medicine|February 21, 2012
Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseasesAlan J Russell, James J Hartman, Aaron C Hinken, et al.
Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.
European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac MyosinBradley P Morgan, Alexander Muci, Pu-Ping Lu, et al.
Narra J|March 7, 2024
Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South AmericaDott F Rosiello, Samsul Anwar, Amanda Yufika, et al.
The Journal of Clinical Investigation|March 23, 2021
Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calciumMartijn van de Locht, Sandra Donkervoort, Josine M de Winter, et al.
European Heart Journal|September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialCaroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.
Pageof 26